Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 2051-2059, 2007. First published September 27, 2007; 10.1373/clinchem.2007.090290
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow 090290.Data Supplement
Right arrow All Versions of this Article:
clinchem.2007.090290v1
53/12/2051    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Google Scholar
Right arrow Articles by Shen, Y.
Right arrow Articles by Wu, B.-L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shen, Y.
Right arrow Articles by Wu, B.-L.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 2007;53:2051-2059.)
© 2007 American Association for Clinical Chemistry, Inc.

Molecular Diagnostics and Genetics

Development of a Focused Oligonucleotide-Array Comparative Genomic Hybridization Chip for Clinical Diagnosis of Genomic Imbalance

Yiping Shen1,2,3, David T. Miller1,3,4,3, Sau Wai Cheung5, Va Lip1, Xiaoming Sheng1, Keith Tomaszewicz1, Hong Shao1, Hong Fang1, Hung Siv Tang1, Mira Irons3,4, Christopher A. Walsh3,4,6, Orah Platt1,4, James F. Gusella2,4 and Bai-Lin Wu1,4,a

1 Department of Laboratory Medicine, Children’s Hospital Boston, Boston, MA.
2 Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA.
3 Division of Genetics, Children’s Hospital Boston, Boston, MA.
4 Departments of Medicine, Neurology, Pathology, Pediatrics, Harvard Medical School, Boston, MA.
5 Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX.
6 Howard Hughes Medical Institute, Chevy Chase, MD.

aAddress correspondence to this author at: Departments of Laboratory Medicine and Pathology, Children’s Hospital and Harvard Medical School, 300 Longwood Ave., Boston, MA 02115. Fax 617-730-0338; e-mail bai-lin.wu{at}childrens.harvard.edu.

Background: Submicroscopic genomic imbalance underlies well-defined microdeletion and microduplication syndromes and contributes to general developmental disorders such as mental retardation and autism. Array comparative genomic hybridization (CGH) complements routine cytogenetic methods such as karyotyping and fluorescence in situ hybridization (FISH) for the detection of genomic imbalance. Oligonucleotide arrays in particular offer advantages in ease of manufacturing, but standard arrays for single-nucleotide polymorphism genotyping or linkage analysis offer variable coverage in clinically relevant regions. We report the design and validation of a focused oligonucleotide-array CGH assay for clinical laboratory diagnosis of genomic imbalance.

Methods: We selected >10 000 60-mer oligonucleotide features from Agilent’s eArray probe library to interrogate all subtelomeric and pericentromeric regions and 95 additional clinically relevant regions for a total of 179 loci. Sensitivity and specificity were measured for 105 patient samples, including 51 with known genomic-imbalance events, as detected by bacterial artificial chromosome–based array CGH, FISH, or multiplex ligation-dependent probe amplification.

Results: Focused array CGH detected all known regions of genomic imbalance in 51 validation samples with 100% concordance and an excellent signal-to-noise ratio. The mean SD among log2 ratios of all noncontrol features without copy number alteration was 0.062 (median, 0.055). Clinical testing of another 211 samples from individuals with developmental delay, unexplained mental retardation, dysmorphic features, or multiple congenital anomalies revealed genomic imbalance in 25 samples (11.9%).

Conclusions: This focused oligonucleotide-array CGH assay, a flexible, robust method for clinically diagnosing genetic disorders associated with genomic imbalance, offers appreciable advantages over currently available platforms.




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Med. Genet.Home page
E Aston, H Whitby, T Maxwell, N Glaus, B Cowley, D Lowry, X L Zhu, B Issa, S T South, and A R Brothman
Comparison of targeted and whole genome analysis of postnatal specimens using a commercially available array based comparative genomic hybridisation (aCGH) microarray platform
J. Med. Genet., May 1, 2008; 45(5): 268 - 274.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.